Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Preclinical Development

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra and N.V. Rajeshkumar
Masamichi Mizuma
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeshaan A. Rasheed
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinichi Yabuuchi
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noriyuki Omura
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathaniel R. Campbell
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roeland F. de Wilde
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth De Oliveira
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Zhang
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar Puig
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Matsui
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Hidalgo
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anirban Maitra
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N.V. Rajeshkumar
Authors' Affiliations: Departments of 1Pathology and 2Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Informatics and Analysis, Merck Research Laboratories, Kenilworth, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-12-0017 Published September 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Chemical structures of MRK-003 and gemcitabine. MRK-003 (A) and gemcitabine (B).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    MRK-003 treatment inhibits anchorage-independent growth of PDAC cell lines, which is rescued by enforced expression of N1ICD. A, downregulation of Hes-1 mRNA is seen in PDAC lines treated with MRK-003. B, colony formation in soft agar is inhibited in Pa03C cells with 5 μmol/L of MRK-003. C, normalized colony counts in PDAC cell lines, pretreated with 2 and 5 μmol/L of MRK-003 (**, P < 0.01). Three of the cells lines (Capan-1, Pa03C, and Pa14C) were sensitive based on significant inhibition of anchorage growth, whereas the other 2 (Pa16C and Pa29C) were resistant. D and E, qRT-PCR and Western blots of N1ICD stably transfected Pa03C, showing overexpression of transcripts corresponding to the ICD domain as compared with mock-transfected cells. F and G, treatment of MRK-003 significantly reduced the number of colonies in mock Pa03C cells, whereas no significant effects are seen in N1ICD expressing Pa03C cells. Notably, expression of N1ICD per se results in a significant expansion of colonies in soft agar in untreated Pa03C compared with the mock controls.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Ex vivo pretreatment with MRK-003 significantly inhibits engraftment in mice. A, representative photographs of mice injected with MRK-003 pretreated Capan-1 and Pa03C cells (tumor generated from vehicle and MRK-003 pretreatment-treated cell lines are on the right and left side of mice, respectively). B, tumor growth curves show that MRK-003 pretreatment significantly delayed engraftment in Capan-1 and Pa03C cells (**, P < 0.01) compared with the tumor generated from vehicle-treated cells. However, MRK-003 pretreatment did not impact the engraftment of Pa16C or Pa29C compared with the tumors generated from vehicle-treated cells.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    MRK-003 treatment modulates the population of tumor-initiating cells in PDAC lines. PDAC cells were treated with MRK-003 (2 or 5 μmol/L) for 48 hours. The cells were harvested and stained for FACS analysis. A, representative data for CD44+CD24+ and ALDH+ population in MRK-003 treated in Capan-1 cells showing reduction of CD44+CD24+ and ALDH+ cells compared with the vehicle-treated cells. B and C, percentage of CD44+CD24+ and ALDH+ population, respectively, in 4 pancreatic cancer cell lines treated with MRK-003 for 48 hours. Dose-dependent reduction in the proportion of CD44+CD24+ and ALDH+ cells were noticed in 2 sensitive cell lines (Capan-1 and Pa03C). However, MRK-003 increased the proportion of CD44+CD24+ and ALDH+ cells in Pa16C and Pa29C. Experiments were conducted in triplicate, N = 3, error bars SD.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    In vivo efficacy of MRK-003, gemcitabine, and combination of MRK-003 and gemcitabine in a panel of patient-derived PDAC xenografts. A, 9 individual cases for this study were selected from a pool of 30 PDAC xenografts based on expression of NOTCH1 transcripts at baseline. In the illustrated heatmap, red to green indicates decreasing transcript expression. The numbers on the top panel indicate each individual patient-derived PDAC xenograft. B, growth curves of 2 representative PDAC xenografts, Panc374 and Panc198, show that the combination of gemcitabine and MRK-003 can significantly inhibit tumor growth compared with the vehicle and/or gemcitabine-treated animals. Each treatment arm was comprised of 10 tumors implanted as bilateral subcutaneous xenografts in 5 mice. C, summary of tumor growth inhibition data. MRK-003 monotherapy significantly reduced tumor volume in 5 of 9 xenografts compared with the vehicle-treated xenografts, which were Panc420, Panc374, Panc219, Panc265, and JH033. There was a significant reduction in tumor growth of 4 of 9 xenografts in the combination therapy group compared with the gemcitabine alone, which were Panc198, Panc219, Panc291, and JH033. (*, P < 0.05, **, P < 0.01, ***, P < 0.001 versus vehicle-treated mice; #, P < 0.05, ##, P < 0.01 compared with the gemcitabine-treated mice). GEM, gemcitabine.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    MRK-003 treatment downregulates nuclear N1ICD and Hes-1 protein expressions in PDAC xenografts as shown by immunohistochemical staining. A and B, representative photomicrographs of N1ICD and Hes-1 from Panc291 and Panc374 xenografts showing downregulation of nuclear N1ICD and Hes-1 expression in MRK-003 and combination of gemcitabine and MRK-003 treatment compared with the vehicle-treated and gemcitabine-treated tumor samples. GEM, gemcitabine.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Combination of gemcitabine and MRK-003 induces apoptosis and reduces cell proliferation in PDAC xenografts. A, representative photomicrograph of TUNEL staining from Panc198 and Panc291. Histogram of TUNEL-positive nuclei per high-power field (bottom), showing that combination of gemcitabine and MRK-003 significantly enhanced apoptotic cells per field as compared with the gemcitabine treatment. B, representative photomicrograph of Ki-67 staining from Panc198 and Panc291. Histogram of Ki-67-positive nuclei per high-power field (bottom), showing that combination of gemcitabine and MRK-003 significantly reduced proliferating cells as compared with the gemcitabine treatment. Histograms for TUNEL and Ki-67 were generated by evaluating 5 high-power fields per xenograft section from 2 independent tumors per treatment arms; mean ± SEM (*, P < 0.001 compared with the gemcitabine). GEM, gemcitabine.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Figure Legend - PDF file, 94K.
    • Supplementary Figure 1 - PDF file, 76K, FACS plots for ALDH and CD44 and CD24 controls.
    • Supplementary Figure 2 - PDF file, 186K, Baseline gene expression profiles identify signatures of response to single agent MRK-003 and the combination of MRK-003 and GEM.
    • Supplementary Figure 3 - PDF file, 209K, Representative H&E stained sections from Panc374 xenograft.
    • Supplementary Table 1 - XLSX file, 105K, Gene expression analysis for predictive signatures of response to MRK-003.
    • Supplementary Table 2 - XLSX file, 138K, Gene expression analysis for predictive signatures of response to MRK-003 plus GEM.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 11 (9)
September 2012
Volume 11, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra and N.V. Rajeshkumar
Mol Cancer Ther September 1 2012 (11) (9) 1999-2009; DOI: 10.1158/1535-7163.MCT-12-0017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra and N.V. Rajeshkumar
Mol Cancer Ther September 1 2012 (11) (9) 1999-2009; DOI: 10.1158/1535-7163.MCT-12-0017
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PSMA-Specific BiTE Antibody
  • BiKEs and TriKEs Enhance NK Cell Effector Function
  • Ganetespib Activity in KRAS-Mutant NSCLCs
Show more Preclinical Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement